Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease

We developed and validated a clinically applicable decision tree for the use of cerebrospinal fluid biomarkers in the diagnosis of Alzheimer's disease (AD).

[1]  C. Jack,et al.  Biomarker Modeling of Alzheimer’s Disease , 2013, Neuron.

[2]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[3]  W. M. van der Flier,et al.  CSF biomarkers in relationship to cognitive profiles in Alzheimer disease , 2009, Neurology.

[4]  J. Kaye,et al.  High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.

[5]  W. M. van der Flier,et al.  Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort , 2012, Neurology.

[6]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[7]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[8]  Reisa A. Sperling,et al.  Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease , 2014, Science Translational Medicine.

[9]  J. Trojanowski,et al.  Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: links to cognition, progression and biomarkers , 2016, Brain : a journal of neurology.

[10]  W. M. van der Flier,et al.  Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ1-42, T-tau, and P-tau values , 2017, Alzheimer's & dementia.

[11]  Frederik Barkhof,et al.  Optimizing patient care and research: the Amsterdam Dementia Cohort. , 2014, Journal of Alzheimer's disease : JAD.

[12]  F. Verhage.  Intelligentie en leeftijd : onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar , 1964 .

[13]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[14]  K. Blennow,et al.  Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. , 2015, Brain : a journal of neurology.

[15]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..

[16]  A. Shah,et al.  ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions , 2013, Proceedings of the National Academy of Sciences.

[17]  R. Marshall.  The use of classification and regression trees in clinical epidemiology. , 2001, Journal of clinical epidemiology.

[18]  W. M. van der Flier,et al.  Amsterdam Dementia Cohort: Performing Research to Optimize Care , 2018, Journal of Alzheimer's disease : JAD.

[19]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[20]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[21]  J. Molinuevo,et al.  Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. , 2012, Biomarkers in medicine.

[22]  S. Lemon,et al.  Classification and regression tree analysis in public health: Methodological review and comparison with logistic regression , 2003, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[23]  W. M. van der Flier,et al.  Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[24]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[25]  P. Scheltens,et al.  Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population , 2017, Alzheimer's Research & Therapy.

[26]  Hilkka Soininen,et al.  Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.

[27]  Hilkka Soininen,et al.  Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers , 2005, Annals of neurology.

[28]  W. M. van der Flier,et al.  Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. , 2018, Clinical chemistry.

[29]  W. M. van der Flier,et al.  Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. , 2010, Clinical chemistry.

[30]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[31]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[32]  K. Blennow,et al.  The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean? , 2014, Alzheimer's & Dementia.

[33]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[34]  Wiesje M. van der Flier,et al.  Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints , 2013, Alzheimer's & Dementia.